Axsome Therapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on February 17, 2026. The report addresses a material event under Item 8.01 (Other Events) concerning the resolution of patent litigation regarding the Company's product SUNOSI (solriamfetol).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal settlement and does not contain financial statement data.
Material Changes and Events
Axsome Therapeutics, Inc. entered into a settlement agreement with Alkem Laboratories Ltd. to resolve patent litigation pending in the U.S. District Court for the District of New Jersey. The litigation arose from Alkem's submission of an Abbreviated New Drug Application for a generic version of SUNOSI.
- Settlement Terms: Axsome will grant Alkem a license to sell the generic version of SUNOSI.
- Effective Dates: The license becomes effective on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if no pediatric exclusivity is granted.
- Conditions: The agreement is subject to FDA approval and customary conditions.
- Regulatory Review: The settlement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Similar patent litigation against another party regarding SUNOSI remains pending.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future performance. The primary risk noted is the regulatory review of the settlement by federal authorities. The text states that the description of the settlement agreement is not complete and refers to the full press release filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the status of the U.S. Federal Trade Commission and Department of Justice review of the settlement.
- Confirm whether pediatric exclusivity for SUNOSI is granted, as this determines the generic entry date (2040).
- Review the status of the remaining pending patent litigation against other parties.
- Examine the full text of the press release (Exhibit 99.1) for complete settlement terms.